Home > Insider Trading > Filing (0001140361-22-044471)

Filing Details

Accession Number:: 0001140361-22-044471
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-12-05 16:44:39
Reporting Period:: 2022-12-01

Accepted Time:: 2022-12-05 16:44:39
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1802768	Royalty Pharma Plc	RPRX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1814877	Ltd Management Skyeline	C/O Gisev Family Office Sa Contrada Di Sassello 2 Lugano V8 6900	No	No	No	No
1814882	Germano Mario Giuliani	C/O Gisev Family Office Sa Contrada Di Sassello 2 Lugano V8 6900	No	No	No	No
1814889	Strategic Mgg - S.a. Sif Sicaf Strategic Mgg	18 Avenue De La Porte Neuve Luxembourg N4 L-2227	No	No	No	No
1814934	Ltd Management Avara	C/O Gisev Family Office Sa Contrada Di Sassello 2 Lugano V8 6900	No	No	No	No
1922189	S.a. Sif Sicaf Strategic Mgg	18 Avenue De La Porte Neuve Luxembourg N4 L-2227	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Ordinary Shares	Disposition	2022-12-01	165,000	$44.11	22,225,000	No	4	S	Indirect	See Footnotes
Class A Ordinary Shares	Disposition	2022-12-02	197,766	$43.98	7,879,374	No	4	S	Indirect	See Footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See Footnotes
No	4	S	Indirect	See Footnotes

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Class A Ordinary Shares	50,000	Indirect	See Footnotes
Class A Ordinary Shares	3,477,520	Indirect	See Footnotes

Footnotes

Reflects securities held directly by MGG Strategic SICAF SIF S.A. - MGG Strategic, a Luxembourg company ("MGG Strategic"). MGG Strategic is a sub-fund managed and administered by MGG Strategic SICAF SIF S.A. ("MGG SICAF"). A board of directors consisting of M. Germano Giuliani, Achille G. Severgnini, Marco Sterzi and Franco Toscano has voting and dispositive power over the securities managed by MGG SICAF. Each member of the board disclaims beneficial ownership over such shares. MGG SICAF is owned by the MGG Trust of which M. Germano Giuliani is the beneficiary. The MGG Trust is the 100% economic owner of the shares held by MGG Strategic. M. Germano Giuliani disclaims beneficial ownership over the shares beneficially owned by MGG Strategic. The trustee of the MGG Trust is GISEV Trustees Limited. The protector of the MGG Trust is Achille G. Severgnini, who has the power to remove and replace the trustee of the MGG Trust.
Each of the Reporting Persons may be deemed to beneficially own the securities reported herein directly or indirectly controlled by it or him, but each (other than the direct holder to the extent of its direct holdings) disclaims beneficial ownership of such securities, except to the extent of such Reporting Person's pecuniary interest therein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the Reporting Persons are the beneficial owners of any securities reported herein or are subject to Section 16.
Reflects securities held directly by Skyeline Management Ltd. Skyeline Management Ltd is wholly-owned by Avara Management Ltd. Avara Management Ltd is wholly-owned by M. Germano Giuliani.
Reflects securities held by the spouse of M. Germano Giuliani.
Reflects securities held directly by Avara Management Ltd.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.005 to $44.19 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.80 to $44.20 per share, inclusive. The Reporting Persons undertake to provide to Royalty Pharma plc, any security holder of Royalty Pharma plc, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.